Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 17/20 | 0.48 |
| ▸ | MAP3K13 | O43283 | 2/20 | 0.46 |
| ▸ | DLK1 | P80370 | 1/20 | 0.46 |
| ▸ | ADK | P55263 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26794869 | 1.00 | MAP3K12 (0.48) | MAP3K12MAP3K13DLK1ADKPDE10A | |
| SCHEMBL25147712 | 0.85 | MAP3K12 (0.50) | MAP3K12MAP3K13DLK1ADK | |
| SCHEMBL15743920 | 0.85 | MAP3K12 (0.50) | MAP3K12MAP3K13DLK1ADK | |
| SCHEMBL15743911 | 0.85 | MAP3K12 (0.50) | MAP3K12MAP3K13DLK1ADK | |
| SCHEMBL18307132 | 0.82 | MAP3K12 (0.48) | MAP3K12MAP3K13DLK1ADKPDE10A | |
| SCHEMBL21588292 | 0.82 | ADK (0.49) | MAP3K12MAP3K13DLK1ADKPDE10A | |
| SCHEMBL17076749 | 0.82 | MAP3K12 (0.54) | MAP3K12MAP3K13DLK1ADK | |
| SCHEMBL21672315 | 0.82 | MAP3K12 (0.54) | MAP3K12MAP3K13DLK1ADK | |
| SCHEMBL21588369 | 0.82 | ADK (0.49) | MAP3K12MAP3K13DLK1ADKPDE10A | |
| SCHEMBL18307182 | 0.82 | MAP3K12 (0.48) | MAP3K12MAP3K13DLK1ADKPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814378-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2023-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814378-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | MAPT, MAP1LC3A, TUBB3 | MAP3K12 1782/4885MAP3K13 1793/4885DLK1 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.